The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.

The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure.
Cell Metab. 2019 Nov 05;30(5):847-849
Authors: Bhatt DL, Verma S, Braunwald E
Abstract
In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher in a new paradigm in the treatment of heart failure.
PMID: 31693879 [PubMed - in process]

Source: Cell Metabolism - November 4, 2019 Category: Cytology Authors: Bhatt DL, Verma S, Braunwald E Tags: Cell Metab Source Type: research